FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Time of Type	e Responses)																	
Name and Address of Reporting Person * Chin Mark				2. Issuer Name and Ticker or Trading Symbol Iterum Therapeutics plc [ITRM]							bol		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director					
(Last) (First) (Middle) C/O ITERUM THERAPEUTICS PLC, BLK 2, FL. 3, HARCOURT CENTRE, HARCOURT ST.				3. Date of Earliest Transaction (Month/Day/Year) 06/23/2021							Year)	_	Officer (giv	re title below)	Oth	er (specify below)		
(Street) DUBLIN, L2 2				4. If Amendment, Date Original Filed(Month/Day/Year)							ay/Year)		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City)		(State)	(Zip)				Table	I - N	on-De	rivative	Securitie	s Acquire	uired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year		2A. Deemed Execution Date, if r) any (Month/Day/Year)		(Inst	(Instr. 8)		4. Securities Acqui (A) or Disposed of (Instr. 3, 4 and 5) (A) or Amount (D)		of (D) Ov Tra	5. Amount of Securities Beneficiall Owned Following Reported Transaction(s) (Instr. 3 and 4)		d	Ownership of B	eneficial wnership				
									conta form ed, Dis	ained in display	n this for ys a curre	m are not ently valid eficially O	required d OMB co	of informa to respond ntrol numb	d unless the		74 (9-02)	
4 mid 0	I.		1	` Y .	ts, c							·		0.71. 0	0.37 1	0 40	144.37	
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction Date Security 3. Transaction Date Execution Date, any (Month/Day/Year) 3. Transaction Date, any (Month/Day/Year) 3. Transaction Date, any (Month/Day/Year) 3. Transaction Date, and Execution Date, any (Month/Day/Year)		rif Transaction of I Code ar) (Instr. 8) Accord of I Code ar)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
									Date Exerci		Expiration Date	Title	Amount or Number of		(Instr. 4)	(Instr. 4)		
				Co	le	V	(A)	(D)					Shares					

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Chin Mark C/O ITERUM THERAPEUTICS PLC, BLK 2 FL. 3, HARCOURT CENTRE, HARCOURT ST. DUBLIN, L2 2	X						

Signatures

/s/ Mark Chin	06/25/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- $\begin{tabular}{ll} \star & If the form is filed by more than one reporting person, see Instruction $4(b)(v)$. \\ \end{tabular}$
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU.

(2) Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended, the RSUs shall vest in full on June 23, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.